blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2571489

EP2571489 - INJECTABLE EMULSION OF SEDATIVE HYPNOTIC AGENT [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.06.2015
Database last updated on 03.01.2025
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL
published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
AstraZeneca AB
151 85 Södertälje / SE
[2013/13]
Inventor(s)01 / BOOTH, Jonathan
AstraZeneca
Charter Way
Macclesfield Cheshire SK10 2NA / GB
02 / DIXON, Leigh
AstraZeneca
Charter Way
Macclesfield Cheshire SK10 2NA / GB
03 / WASHINGTON, Clive
AstraZeneca
Charter Way
Macclesfield Cheshire SK10 2NA / GB
 [2013/13]
Application number, filing date11786988.312.05.2011
WO2011SE50602
Priority number, dateUS20100334208P13.05.2010         Original published format: US 334208 P
[2013/13]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011149412
Date:01.12.2011
Language:EN
[2011/48]
Type: A1 Application with search report 
No.:EP2571489
Date:27.03.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 01.12.2011 takes the place of the publication of the European patent application.
[2013/13]
Type: B1 Patent specification 
No.:EP2571489
Date:06.08.2014
Language:EN
[2014/32]
Search report(s)International search report - published on:SE01.12.2011
(Supplementary) European search report - dispatched on:EP19.08.2013
ClassificationIPC:A61K9/107, A61K31/216, A61K47/14, A61P23/00
[2013/38]
CPC:
A61K9/0019 (EP,US); A61K9/107 (KR,US); A61K31/216 (EP,KR,US);
A61K47/10 (EP,US); A61K47/14 (EP,US); A61K47/24 (EP,US);
A61K47/44 (EP,US); A61K9/1075 (EP,US); A61P23/00 (EP);
A61P25/20 (EP) (-)
Former IPC [2013/13]A61K9/107, A61K31/216, A61P23/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/13]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:INJIZIERBARE EMULSION AUS EINEM SEDATIVEN HYPNOSEMITTEL[2013/13]
English:INJECTABLE EMULSION OF SEDATIVE HYPNOTIC AGENT[2013/13]
French:EMULSION INJECTABLE D'UN AGENT HYPNOTIQUE SÉDATIF[2013/13]
Entry into regional phase13.12.2012National basic fee paid 
13.12.2012Search fee paid 
13.12.2012Designation fee(s) paid 
14.11.2012Examination fee paid 
Examination procedure14.11.2012Examination requested  [2013/13]
02.07.2013Amendment by applicant (claims and/or description)
16.09.2013Despatch of a communication from the examining division (Time limit: M04)
21.01.2014Reply to a communication from the examining division
17.02.2014Communication of intention to grant the patent
19.05.2014Receipt of the translation of the claim(s)
27.06.2014Fee for grant paid
27.06.2014Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  16.09.2013
Opposition(s)07.05.2015No opposition filed within time limit [2015/29]
Fees paidRenewal fee
31.05.2013Renewal fee patent year 03
02.06.2014Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU12.05.2011
AL06.08.2014
AT06.08.2014
BE06.08.2014
CY06.08.2014
CZ06.08.2014
DK06.08.2014
EE06.08.2014
FI06.08.2014
HR06.08.2014
LT06.08.2014
LV06.08.2014
MC06.08.2014
MK06.08.2014
MT06.08.2014
PL06.08.2014
RO06.08.2014
RS06.08.2014
SI06.08.2014
SK06.08.2014
SM06.08.2014
TR06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
IS06.12.2014
PT09.12.2014
[2018/46]
Former [2018/31]HU12.05.2011
AT06.08.2014
BE06.08.2014
CY06.08.2014
CZ06.08.2014
DK06.08.2014
EE06.08.2014
FI06.08.2014
HR06.08.2014
LT06.08.2014
LV06.08.2014
MC06.08.2014
MK06.08.2014
MT06.08.2014
PL06.08.2014
RO06.08.2014
RS06.08.2014
SI06.08.2014
SK06.08.2014
SM06.08.2014
TR06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
IS06.12.2014
PT09.12.2014
Former [2017/38]HU12.05.2011
AT06.08.2014
BE06.08.2014
CY06.08.2014
CZ06.08.2014
DK06.08.2014
EE06.08.2014
FI06.08.2014
HR06.08.2014
LT06.08.2014
LV06.08.2014
MC06.08.2014
MT06.08.2014
PL06.08.2014
RO06.08.2014
RS06.08.2014
SI06.08.2014
SK06.08.2014
SM06.08.2014
TR06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
IS06.12.2014
PT09.12.2014
Former [2017/03]AT06.08.2014
BE06.08.2014
CY06.08.2014
CZ06.08.2014
DK06.08.2014
EE06.08.2014
FI06.08.2014
HR06.08.2014
LT06.08.2014
LV06.08.2014
MC06.08.2014
MT06.08.2014
PL06.08.2014
RO06.08.2014
RS06.08.2014
SI06.08.2014
SK06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
IS06.12.2014
PT09.12.2014
Former [2016/32]AT06.08.2014
BE06.08.2014
CY06.08.2014
CZ06.08.2014
DK06.08.2014
EE06.08.2014
FI06.08.2014
HR06.08.2014
LT06.08.2014
LV06.08.2014
MC06.08.2014
PL06.08.2014
RO06.08.2014
RS06.08.2014
SI06.08.2014
SK06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
IS06.12.2014
PT09.12.2014
Former [2016/06]AT06.08.2014
CY06.08.2014
CZ06.08.2014
DK06.08.2014
EE06.08.2014
FI06.08.2014
HR06.08.2014
LT06.08.2014
LV06.08.2014
MC06.08.2014
PL06.08.2014
RO06.08.2014
RS06.08.2014
SI06.08.2014
SK06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
IS06.12.2014
PT09.12.2014
Former [2015/50]AT06.08.2014
CY06.08.2014
CZ06.08.2014
DK06.08.2014
EE06.08.2014
FI06.08.2014
HR06.08.2014
LT06.08.2014
LV06.08.2014
PL06.08.2014
RO06.08.2014
RS06.08.2014
SI06.08.2014
SK06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
IS06.12.2014
PT09.12.2014
Former [2015/23]AT06.08.2014
CY06.08.2014
CZ06.08.2014
DK06.08.2014
EE06.08.2014
FI06.08.2014
HR06.08.2014
LT06.08.2014
LV06.08.2014
PL06.08.2014
RO06.08.2014
RS06.08.2014
SK06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
IS06.12.2014
PT09.12.2014
Former [2015/22]AT06.08.2014
CY06.08.2014
DK06.08.2014
FI06.08.2014
HR06.08.2014
LT06.08.2014
LV06.08.2014
PL06.08.2014
RO06.08.2014
RS06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
IS06.12.2014
PT09.12.2014
Former [2015/12]AT06.08.2014
CY06.08.2014
FI06.08.2014
HR06.08.2014
LT06.08.2014
LV06.08.2014
PL06.08.2014
RS06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
IS06.12.2014
PT09.12.2014
Former [2015/11]CY06.08.2014
FI06.08.2014
LT06.08.2014
PL06.08.2014
BG06.11.2014
NO06.11.2014
GR07.11.2014
PT09.12.2014
Former [2015/10]FI06.08.2014
LT06.08.2014
BG06.11.2014
NO06.11.2014
Former [2015/09]FI06.08.2014
LT06.08.2014
Former [2015/08]LT06.08.2014
Documents cited:Search[X]US2003153554  (JENKINS THOMAS E [US], et al) [X] 1-15 * paragraph [0076]; example 16; table I; compound 1 *;
 [Y]WO2005009420  (THERAVANCE INC [US], et al) [Y] 1-15 * page 4, line 33 - page 5, line 7; example 6; table 4 *;
 [XY]EP1875901  (OTSUKA PHARMA CO LTD [JP]) [X] 14 * paragraphs [0020] , [0031] , [0033] , [0039] - [0043]; examples 1-3; table 1 * [Y] 1-15;
 [Y]US4711902  (SERNO PETER [DE]) [Y] 1-15 * column 5, lines 1-19; example - * * column 6, lines 29-36 *
International search[X]WO2005009420  (THERAVANCE INC [US], et al);
 [X]US2003153554  (JENKINS THOMAS E [US], et al);
 [X]EP1875901  (OTSUKA PHARMA CO LTD [JP]);
 [A]EP0211258  (ABBOTT LAB [US])
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.